PendasS., DauwayE., CoxC.E.. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients.Am Surg.1999; 65: 500–506.
2.
TurnerR.R., OllilaD.W., KrasneD.L.. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.Ann Surg.1997; 226: 271–278.
3.
TurnerR.R., GiulianoA.E., HoonD.S.. Pathologic examination of sentinel lymph node for breast carcinoma.World J Surg.2001; 25: 798–805.
4.
SabelM.S., ZhangP., BarnwellJ.M.. Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma.J Surg Oncol.2001; 77: 243–246.
5.
JakubJ.W., DiazN.M., EbertM.D.. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes.Am J Surg.2002; 184: 302–306.
6.
GreeneF.L., ed. AJCC Cancer Staging Manual: American Joint Committee on Cancer.6th ed.New York, NY: Springer Verlag; 2002.
7.
CarterB.A., JensenR.A., SimpsonJ.F.. Benign transport of breast epithelium into axillary lymph nodes after biopsy.Am J Clin Pathol.2000; 113: 259–265.
8.
IkomiF., HuntJ., HannaG.. Interstitial fluid, plasma protein, colloid, and leukocyte uptake into initial lymphatics.J Appl Physiol.1996; 81: 2060–2067.
9.
CadyB.. Selective management of axilla in minimally invasive and early invasive ductal carcinoma. In: BlandK.I., CopelandE.M., eds. The Breast: Comprehensive Management of Benign and Malignant Diseases.2nd ed.Philadelphia, Pa: WB Saunders Co; 1998.
10.
DessureaultS., SoongS.J., RossM.I.. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy.Ann Surg Oncol.2001; 8: 766–770.
11.
WinerE.P., MorrowM., OsborneC.K.. Cancer of the breast: malignant tumors of the breast. In: DeVitaV.T., HellmanS., RosenburgS.A., eds. Cancer: Principles and Practice of Oncology.6th ed.Philadelphia, Pa: Lippincott Williams and Wilkins; 2001.